prostate specific antigen

Summary

Gene Symbol: prostate specific antigen
Description: kallikrein related peptidase 3
Alias: APS, KLK2A1, PSA, hK3, prostate-specific antigen, P-30 antigen, gamma-seminoprotein, kallikrein-3, semenogelase, seminin
Species: human

Top Publications

  1. ncbi Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma
    P Cohen
    Department of Pediatrics, Stanford University Medical Center, California 94305
    J Clin Endocrinol Metab 75:1046-53. 1992
  2. ncbi Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors
    A Christensson
    Department of Clinical Chemistry, University of Lund, Malmo General Hospital, Sweden
    Eur J Biochem 194:755-63. 1990
  3. pmc Human prostate-specific antigen: structural and functional similarity with serine proteases
    K W Watt
    Proc Natl Acad Sci U S A 83:3166-70. 1986
  4. pmc A structural model for the prostate disease marker, human prostate-specific antigen
    B O Villoutreix
    Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037
    Protein Sci 3:2033-44. 1994
  5. ncbi Substrate specificity of prostate-specific antigen (PSA)
    G S Coombs
    Corvas International, Department of Molecular Biology, San Diego, CA 92121, USA
    Chem Biol 5:475-88. 1998
  6. pmc Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen
    H H Heidtmann
    St Joseph Hospital, Bremerhaven, Germany
    Br J Cancer 81:1269-73. 1999
  7. ncbi Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor
    J Malm
    Section for Clinical Chemistry, Department of Laboratory Medicine, Lund University, University Hospital Malmo, Malmo, Sweden
    Prostate 45:132-9. 2000
  8. ncbi Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region
    L Gan
    Chiroscience R and D Inc 1631 220th St SE Bothell, WA 98021, USA
    Gene 257:119-30. 2000
  9. ncbi Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models
    S R Denmeade
    The Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Baltimore, Maryland 21231, USA
    Prostate 48:1-6. 2001
  10. ncbi Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells
    Rui Medeiros
    Molecular Oncology Unit, Instituto Portugues de Oncologia, Porto, Portugal
    Prostate 53:88-94. 2002

Research Grants

  1. Pamela L Paris; Fiscal Year: 2015
  2. Kathryn Radabaugh Nightingale; Fiscal Year: 2014
  3. A Serum Marker for Aggressive Prostate Cancer
    Donna M Peehl; Fiscal Year: 2010
  4. Alicia C McDonald; Fiscal Year: 2015
  5. Detecting Prostate Cancer using multi-protocol 3 Tesla in vivo MRI and MRS
    Anant Madabhushi; Fiscal Year: 2009
  6. A bioelectronic assay for PSA activity
    Dimitra Georganopoulou; Fiscal Year: 2010
  7. Sebastiano Gattoni-Celli; Fiscal Year: 2016
  8. Glycan Biomarkers of Prostate Cancer in Prostatic Fluids
    Richard R Drake; Fiscal Year: 2012
  9. DAVID MICHAEL SCHUSTER; Fiscal Year: 2016
  10. Russell S Taichman; Fiscal Year: 2015

Patents

  1. Human cDNAs and proteins and uses thereof

Detail Information

Publications600 found, 100 shown here

  1. ncbi Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma
    P Cohen
    Department of Pediatrics, Stanford University Medical Center, California 94305
    J Clin Endocrinol Metab 75:1046-53. 1992
    ..Prostate-specific antigen (PSA) is a serine protease found in semen...
  2. ncbi Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors
    A Christensson
    Department of Clinical Chemistry, University of Lund, Malmo General Hospital, Sweden
    Eur J Biochem 194:755-63. 1990
    Prostate-specific antigen (PSA) is one of the three most abundant prostatic-secreted proteins in human semen...
  3. pmc Human prostate-specific antigen: structural and functional similarity with serine proteases
    K W Watt
    Proc Natl Acad Sci U S A 83:3166-70. 1986
    ....
  4. pmc A structural model for the prostate disease marker, human prostate-specific antigen
    B O Villoutreix
    Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037
    Protein Sci 3:2033-44. 1994
    Prostate-specific antigen (PSA) provides an excellent serum marker for prostate cancer, the most frequent form of cancer in American males. PSA is a 237-residue protease based on sequence homology to kallikrein-like enzymes...
  5. ncbi Substrate specificity of prostate-specific antigen (PSA)
    G S Coombs
    Corvas International, Department of Molecular Biology, San Diego, CA 92121, USA
    Chem Biol 5:475-88. 1998
    The serine protease prostate-specific antigen (PSA) is a useful clinical marker for prostatic malignancy...
  6. pmc Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen
    H H Heidtmann
    St Joseph Hospital, Bremerhaven, Germany
    Br J Cancer 81:1269-73. 1999
    ..It is generated from plasminogen by limited proteolysis. We show that prostate-specific antigen (PSA), a serine proteinase secreted by human prostate and human prostate cancer cells, is able to convert Lys-..
  7. ncbi Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor
    J Malm
    Section for Clinical Chemistry, Department of Laboratory Medicine, Lund University, University Hospital Malmo, Malmo, Sweden
    Prostate 45:132-9. 2000
    In semen, prostate-specific antigen (PSA or hK3) digests the gel proteins semenogelin I and II, resulting in liquefaction and the release of motile spermatozoa...
  8. ncbi Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region
    L Gan
    Chiroscience R and D Inc 1631 220th St SE Bothell, WA 98021, USA
    Gene 257:119-30. 2000
    ..The proteases, excluding the kallikrein genes, share approximately 40% of their sequences suggesting that the serine protease gene cluster on chromosome 19q13 arose from ancient gene duplications...
  9. ncbi Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models
    S R Denmeade
    The Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Baltimore, Maryland 21231, USA
    Prostate 48:1-6. 2001
    Prostate-specific antigen (PSA) targeted prodrugs are under development in our laboratory...
  10. ncbi Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells
    Rui Medeiros
    Molecular Oncology Unit, Instituto Portugues de Oncologia, Porto, Portugal
    Prostate 53:88-94. 2002
    The prostate specific antigen (PSA) gene has a polymorphic androgen response element (ARE) sequence with two alleles, A and G. PSA A-allele carriers have higher serum PSA levels in healthy men (HM).
  11. ncbi Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk
    Andrea Gsur
    Division of Applied and Experimental Oncology, Institute of Cancer Research, University of Vienna, Austria
    Carcinogenesis 23:1647-51. 2002
    ..by binding to androgen-response elements (AREs) in target genes, such as the prostate-specific antigen (PSA). In the ARE-I sequence of the PSA gene an adenine to guanine polymorphism is described...
  12. ncbi Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion
    Kenichiro Ishii
    Laboratory of Pharmaceutics, Gifu Pharmaceutical University, 5 6 1 Mitahora Higashi, Gifu 502 8585, Japan
    Cancer Lett 207:79-87. 2004
    Prostate-specific antigen (PSA), which is used as a marker for the diagnosis and monitoring of prostate cancer, is a kallikrein protease which could potentially play a role in human prostate cancer cell invasion...
  13. ncbi Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen
    S L Dallas
    Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    J Cell Physiol 202:361-70. 2005
    ..We investigated whether prostate specific antigen (PSA), a serine protease used as a clinical marker for prostate cancer, could play a role in the ..
  14. ncbi Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3
    Piotr Laidler
    Institute of Medical Biochemistry, Jagiellonian University, Medical College, ul Kopernika 7, 31 034 Krakow, Poland
    Arch Biochem Biophys 435:1-14. 2005
    ..The values of interaction force between the same anti-PSMA antibodies and all studied cells were almost identical (45-64pN), indicating antigenic similarity of the membrane form of PSMA expressed in LNCaP, PC-3, and Du 145 cells...
  15. ncbi Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness
    Mine S Cicek
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Lerner School of Medicine, Ohio, USA
    Cancer Epidemiol Biomarkers Prev 14:2173-7. 2005
    ..androgen metabolism: CYP1B1 (two single nucleotide polymorphisms: 355G/T and 4326C/G), prostate-specific antigen (PSA/KLK3 (three single nucleotide polymorphisms: -158A/G, -4643G/A, and -5412C/T), and CYP11alpha [(tttta)(n) repeat], ..
  16. ncbi Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African-American men
    J L Beebe-Dimmer
    Department of Urology, University of Michigan Medical School, Ann Arbor MI, USA
    Prostate Cancer Prostatic Dis 9:50-5. 2006
    A major problem with the use of serum prostate-specific antigen (PSA) in predicting prostate cancer risk is the considerable variability of such measurements. Cramer et al...
  17. ncbi Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA
    Gianluca Severi
    Cancer Epidemiology Center, The Cancer Council Victoria, Melbourne, Victoria, Australia
    Cancer Epidemiol Biomarkers Prev 15:1142-7. 2006
    An A to G substitution, rs925013, in the promoter of the prostate-specific antigen gene (PSA) was recently found to be associated with promoter activity and circulating PSA levels...
  18. doi Multiple newly identified loci associated with prostate cancer susceptibility
    Rosalind A Eeles
    The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
    Nat Genet 40:316-21. 2008
    ..or with a family history of disease, and 1,894 population-screened controls with a low prostate-specific antigen (PSA) concentration (<0.5 ng/ml). We analyzed these samples for 541,129 SNPs using the Illumina Infinium platform...
  19. doi PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy
    Rodrigo Mattos dos Santos
    Institute of Biosciences, Sao Paulo State University, UNESP, Botucatu, Sao Paulo, Brazil
    DNA Cell Biol 27:497-503. 2008
    The aim of the present study was to examine the impact of polymorphisms in prostate-specific antigen (PSA) and androgen-related genes (AR, CYP17, and CYP19) on prostate cancer (PCa) risk in selected high-risk patients who underwent ..
  20. pmc Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels
    C Jesser
    Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    Br J Cancer 99:1743-7. 2008
    Prostate-specific antigen (PSA) is a protease produced in the prostate that cleaves insulin-like growth factor binding protein-3 and other proteins...
  21. pmc Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, 307 E 63rd St, New York, NY 10021, USA
    Eur Urol 56:753-60. 2009
    It has been suggested that changes in prostate-specific antigen (PSA) over time (ie, PSA velocity [PSAV]) aid prostate cancer detection. Some guidelines do incorporate PSAV cut points as an indication for biopsy.
  22. pmc A comprehensive resequence analysis of the KLK15-KLK3-KLK2 locus on chromosome 19q13.33
    Hemang Parikh
    Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Gaithersburg, MD 20877, USA
    Hum Genet 127:91-9. 2010
    ..33 are associated with serum prostate-specific antigen (PSA) levels...
  23. doi Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells
    Astrid K Whitbread
    Institute of Health and Biomedical Innovation and School of Life Sciences, Queensland University of Technology, Australia
    Biol Chem 391:461-6. 2010
    b>PSA-RP2 is a variant transcript expressed from the PSA gene that is conserved in gorillas, chimpanzees and humans suggesting a particular relevance for this transcript in these primates...
  24. pmc Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies
    Awatef Ben Jemaa
    Unit of Immunology and Microbiology Environmental and Carcinogenesis, Faculty of Sciences of Bizerte, 7021 Zarzouna, University of 7 November at Carthage, Tunisia
    J Exp Clin Cancer Res 29:171. 2010
    The present study was undertaken to relate the co-expression of prostate-associated antigens, PSMA and PSA, with the degree of vascularization in normal and pathologic (hyperplasia and cancer) prostate tissues to elucidate their possible ..
  25. ncbi Association of G/A polymorphism, rs266882, in AREI region of the prostate-specific antigen gene with prostate cancer risk and clinicopathological features
    Mohammad Samzadeh
    Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    Urol J 9:691-9. 2012
    To determine the association of prostate-specific antigen (PSA) 158A/G polymorphism with clinicopathologic characteristics of the disease and prostate cancer (PCa) risk.
  26. ncbi Growth regulation of prostatic stromal cells by prostate-specific antigen
    D M Sutkowski
    Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Natl Cancer Inst 91:1663-9. 1999
    Prostate-specific antigen (PSA) is a serine protease that can cleave insulin-like growth factor-binding protein-3 (IGFBP3), thereby decreasing its affinity for insulin-like growth factor-I (IGF-I)...
  27. ncbi Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels
    Scott D Cramer
    Department of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Natl Cancer Inst 95:1044-53. 2003
    Recent evidence suggests that genetic variation in the promoter of the prostate-specific antigen (PSA) gene may contribute to individual variation in serum PSA levels...
  28. ncbi Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population
    Li Zhong Wang
    Department of Urology, Akita University School of Medicine, 1 1 1 Hondo, Akita 010 8543, Japan
    Cancer Lett 202:53-9. 2003
    Recent studies have indicated that the prostate-specific antigen (PSA) gene polymorphisms may be associated with the risk of prostate cancer in Caucasian populations...
  29. ncbi The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer
    Chih Hung Chiang
    Department of Surgery, Taipei Veterans General Hospital, School of Medicine, National Yang Ming University, Taipei, Taiwan, Republic of China
    J Urol 171:1529-32. 2004
    ..guanine (G) substitution is identified at position -158 in the androgen response elements region of the prostate specific antigen (PSA) gene...
  30. ncbi Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer
    Margaret C Binnie
    Prostate Research Group, Division of Oncology, School of Molecular and Clinical Medicine, Western General Hospital, Edinburgh, United Kingdom
    Prostate 63:309-15. 2005
    Recent data has suggested that polymorphisms in the prostate specific antigen (PSA) may increase prostate cancer (PC) risk. The PSA gene contains a G/A substitution in the androgen response element (ARE) 1 region...
  31. ncbi Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer
    Georg Schatzl
    Department of Urology, Medical University of Vienna, Vienna, Austria
    Urology 65:1141-5. 2005
    To examine the impact of polymorphism in the androgen-responsive element I region of the prostate-specific antigen (PSA) gene on the serum testosterone level and Gleason score in patients with newly diagnosed, untreated prostate cancer (..
  32. ncbi Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells
    T L Veveris-Lowe
    School of Life Sciences and Science Research Centre, Queensland University of Technology, Brisbane, Australia
    Endocr Relat Cancer 12:631-43. 2005
    Prostate-specific antigen (PSA) and the related kallikrein family of serine proteases are current or emerging biomarkers for prostate cancer detection and progression...
  33. ncbi Genetic Susceptibility to Prostate Cancer: Prostate-specific Antigen and its Interaction with the Androgen Receptor (United States)
    Weiva Sieh
    Division of Medical Genetics, Department of Medicine, University of Washington, Box 357720, Seattle, WA, 98195 7720, USA
    Cancer Causes Control 17:187-97. 2006
    To determine whether directly observed prostate-specific antigen (PSA) promoter diploid haplotype, either alone or in conjunction with androgen receptor (AR) genotype, is associated with prostate cancer risk.
  34. ncbi Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin
    Prodipto Pal
    Department of Environmental Health, Center for Genome Information, University of Cincinnati Medical Center, OH 45267 0056, USA
    Hum Genet 122:251-9. 2007
    ..Four of the studied SNPs show positive associations with serum PSA levels...
  35. doi Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancer
    Georgios Pampalakis
    Department of Pharmacy, University of Patras, Rion Patras 26500, Greece
    Clin Biochem 41:591-7. 2008
    We aimed to identify novel splice variants of prostate-specific antigen/or human kallikrein 3 (PSA/KLK3), the most widely used serum biomarker for case-finding, screening and monitoring of prostate cancer.
  36. doi An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines
    Miltiadis Paliouras
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5G 1L5, ON, Canada
    Biol Chem 389:773-80. 2008
    ..itself in several forms, including a percentage of cancers that show reduced levels of prostate-specific antigen (PSA) and can progress without the need for the ligand or active receptor...
  37. pmc Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer
    Scott D Cramer
    Department of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Cancer Epidemiol Biomarkers Prev 17:2451-7. 2008
    The serum test for the secreted protease prostate-specific antigen (PSA) is the most widely used screening tool for prostate cancer...
  38. pmc Association of prostate cancer risk variants with clinicopathologic characteristics of the disease
    Jianfeng Xu
    Center for Cancer Genomics, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Clin Cancer Res 14:5819-24. 2008
    ..Fifteen independent genetic variants have been implicated in prostate cancer risk by recent genome-wide association studies. However, their association with clinicopathologic features of prostate cancer is uncertain...
  39. pmc Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients
    A Karim Kader
    Center for Cancer Genomics, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Prostate 69:1195-205. 2009
    ..Their association with PCa aggressiveness and clinicopathologic variables is inconclusive...
  40. pmc Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer
    Robert J Klein
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Prev Res (Phila) 3:611-9. 2010
    ..of the prostate: KLK2 (encoding kallikrein-related peptidase 2; hK2), KLK3 (encoding prostate-specific antigen; PSA), and MSMB (encoding beta-microseminoprotein)...
  41. ncbi PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility
    John Lai
    Cluster for Molecular Biotechnology, School of Life Sciences and Science Research Centre, Queensland University of Technology, Victoria Park Road, Kelvin Grove, Brisbane, QLD 4059, Australia
    Carcinogenesis 28:1032-9. 2007
    The proximal promoter of the kallikrein-related peptidase 3 gene (KLK3/PSA) contains a single-nucleotide polymorphism (G-158A) located within the second canonical half-site for the prostate-specific antigen (PSA) androgen response ..
  42. ncbi Biochemical characteristics and recent biological knowledge on prostate-specific antigen
    E Seregni
    Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
    Tumori 82:72-7. 1996
    ..in 1971, much new information has been obtained about the biology and expression of prostate-specific antigen (PSA)...
  43. pmc Racial differences in the androgen/androgen receptor pathway in prostate cancer
    C A Pettaway
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    J Natl Med Assoc 91:653-60. 1999
    ..Collectively, these data strongly suggest racial differences within the androgen/androgen receptor pathway not only exist but could be one cause of clinically observed differences in the biology of prostate cancer among racial groups...
  44. ncbi Is acid phosphatase (PAP) still justified in the management of prostatic cancer?
    M Kontturi
    Department of Surgery, Oulu University Central Hospital, Finland
    Acta Oncol 30:169-70. 1991
    The usefulness of acid phosphatase (PAP) and prostate specific antigen (PSA) is compared...
  45. ncbi Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features
    W Demark-Wahnefried
    Division of Urologic Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Urology 58:47-52. 2001
    ..58); however, among men with Gleason sums of 6 or less (n = 19), the PSA values were 7.1 +/- 3.9 ng/mL and 6.4 +/- 4.1 ng/mL (P = 0.10). The mean proliferation index was 7.4 +/- 7...
  46. ncbi Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
    J W Simons
    Johns Hopkins Oncology Center, Brady Urological Institute, and Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer Res 59:5160-8. 1999
    ..No antibodies against prostate-specific antigen were detected. These data suggest that both T-cell and B-cell immune responses to human PCA can be generated by treatment with irradiated, GM-CSF gene-transduced PCA vaccines...
  47. pmc Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patients
    S O Asbell
    Albert Einstein Medical Center, Department of Radiation Oncology, Philadelphia, Pennsylvania, USA
    J Natl Med Assoc 92:445-9. 2000
    ..Blood from 38 screened men (mean age 65) with prostate-specific antigen (PSA) less than 4 ng/mL and normal rectal examination seen at the AEMC Cancer Center was studied using standard ..
  48. pmc Diagnosis and treatment of benign prostatic hyperplasia. Practice patterns of primary care physicians
    M M Collins
    General Medicine Division, Massachusetts General Hospital, Boston 02114, USA
    J Gen Intern Med 12:224-9. 1997
    ..Some of their diagnostic evaluations vary from the recommendations of a national guideline and urologists' practices. Referral thresholds appear to vary considerably...
  49. ncbi Alpha 2-macroglobulin-mediated degradation of amyloid beta 1--42: a mechanism to enhance amyloid beta catabolism
    D Lauer
    Institute of Biochemistry, University of Leipzig, Liebigstrasse 16, 04103 Leipzig, Germany
    Exp Neurol 167:385-92. 2001
    ..These results suggest that up-regulation of A beta catabolism could probably reduce the risk of developing AD by preventing A beta accumulation in brain and vasculature...
  50. pmc Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer
    S Vijayakumar
    Department of Radiation Oncology, Michael Reese Hospital, Center for Radiation Therapy, University of Chicago, Illinois, USA
    J Natl Med Assoc 87:813-9. 1995
    ..free testosterone, androstenedione, luteinizing hormone, or prolactin) have any influence on serum prostate specific antigen (PSA) levels in patients with stage A-C prostate cancer...
  51. ncbi Prostate specific antigen. A review
    M K Brawer
    Department of Urology, University of Washington, Seattle
    Acta Oncol 30:161-8. 1991
    Despite its identification in the 1970s, prostate specific antigen (PSA) has only recently gained widespread utility...
  52. ncbi The role of free to total prostate-specific antigen ratio for prostate cancer in screening patients with total serum levels between 4 and 20 ng/ml
    C T Wu
    Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Taipei
    Chang Gung Med J 23:142-8. 2000
    BACKGROUND: We retrospectively tried to determine if the free to total prostate-specific antigen (f/t PSA) ratio could improve the specificity of PSA in prostate cancer screening of patients with total serum levels between 4 and 20 ng/ml...
  53. pmc Prostate-specific antigen testing practices and outcomes
    R M Hoffman
    Department of Medicine, Albuquerque Veterans Affairs Medical Center, University of New Mexico, 87108, USA
    J Gen Intern Med 13:106-10. 1998
    OBJECTIVES: To characterize prostate-specific antigen (PSA) testing practices in a hospital-based primary care clinic, and to determine the outcomes of PSA testing, including urology referrals, biopsies, cancers detected, and cancer ..
  54. pmc Prostate cancer screening practices and beliefs
    J D Voss
    Division of General Medicine, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Gen Intern Med 16:831-7. 2001
    OBJECTIVE: To examine primary care physician prostate-specific antigen (PSA) testing and prostate cancer screening beliefs, practices, and trends over time. DESIGN: Longitudinal physician survey...
  55. ncbi The importance of patient preference in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team
    A B Flood
    Department of Community and Family Medicine, Dartmouth Medical School, Hanover, NH 03755-3863, USA
    J Gen Intern Med 11:342-9. 1996
    ..This study examines how information about prostate-specific antigen (PSA) testing and the uncertain benefits of treating prostate cancer affects patients' desire for PSA testing...
  56. pmc Correlation of digital rectal examination, prostate specific antigen, and transrectal ultrasound in prostate carcinoma in African Americans
    R I Sibley
    Sibley Medical Associates, Hampton, Virginia, USA
    J Natl Med Assoc 89:318-23. 1997
    ..include the two most cost-effective methods of early detection, digital rectal examination and prostate specific antigen. The use of transrectal ultrasound and guided biopsy improves the yield...
  57. ncbi The IGF axis in the prostate
    P Cohen
    Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia
    Horm Metab Res 26:81-4. 1994
    ..PC-E are exquisitely sensitive to the mitogenic effects of IGFs. Finally, prostate specific antigen (PSA), secreted from PC- and found in seminal plasma, can function as a potent IGFBP-3 protease...
  58. ncbi Comparing two modalities of screening for prostate cancer: digital rectal examination + transrectal ultrasonography vs. prostate-specific antigen
    S Ciatto
    Centro per lo Studio e la Prevenzione Oncologica, Florence, Italy
    Tumori 81:225-9. 1995
    ..examination (DRE) and transrectal ultrasonography (TRUS), or by serum prostate-specific antigen determination (PSA: cutoff 4 ng/ml)...
  59. pmc Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements
    W J Shih
    University of Kentucky Medical Center, Lexington
    J Natl Med Assoc 84:1049-50. 1992
    ..between Gleason scores of histopathology of prostate carcinoma and concurrent serum prostate-specific antigen (PSA) and prostate acid phosphatase (PAP) values, 65 men with prostate carcinoma were studied...
  60. ncbi Serum tumour markers in human prostatic carcinoma. The value of a marker panel for prognostic information
    P Ekman
    Department of Urology, Karolinska Hospital, Stockholm, Sweden
    Acta Oncol 30:173-5. 1991
    Serum from 102 patients was analysed with regard to its content of prostatic acid phosphatase (PAP), prostate specific antigen (PSA), neopterin, osteocalcin, thymidine kinase, C-reactive protein, and of tissue polypeptide antigen (TPA)...
  61. ncbi Involvement of the C-terminal end of the prostrate-specific antigen in a conformational epitope: characterization by proteolytic degradation of monoclonal antibody-bound antigen and mass spectrometry
    S Michel
    , , Marcy l'Etoile, France
    J Mol Recognit 14:406-13. 2001
    Prostate-specific antigen (PSA), a 237-amino acid glycoprotein, encoded by the hKLK3 gene, is widely used as a serum marker for the diagnosis and management of prostate cancer...
  62. pmc Changes in radical prostatectomy and radiation therapy rates for African Americans and whites
    M Shaw
    Division of Cellular Biology, Hektoen Institute for Medical Research, Chicago, IL 60612, USA
    J Natl Med Assoc 92:281-4. 2000
    ..changes in diagnosis rates of localized prostate cancer between the years before prostate-specific antigen (PSA) use (1973-1988) and the years after PSA use (1989-1996), to evaluate differences in RP and RT rates between the ..
  63. ncbi Roach's mathematical equations in predicting pathological stage in men with clinically localized prostate cancer
    M Medica
    Luciano Giuliani Department of Urology, San Martino Hospital, University of Genoa, Italy
    Tumori 87:130-3. 2001
    ..Patients were divided into 25 groups, depending on preoperative PSA and the biopsy Gleason score...
  64. ncbi Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases
    D Fontana
    Dipartimento di Scienze Cliniche e Biologiche, , Italy
    Tumori 84:39-44. 1998
    ..In conclusion, the results, although inconclusive, fail to support a clear advantage in terms of cost/benefit of chemotherapy plus hormone therapy over hormone treatment alone in advanced prostate cancer with bone involvement...
  65. ncbi Digital rectal examination versus transrectal ultrasound in detection of prostate cancer. Preliminary results from a study of a randomly selected population
    U Norming
    Department of Urology, , Stockholm, Sweden
    Acta Oncol 30:277-9. 1991
    ..compared the diagnostic value of digital rectal examination (DRE), transrectal ultrasound (TRUS) and prostate specific antigen (PSA). Altogether 62 prostate cancers were detected, corresponding to a detection rate of 3...
  66. ncbi Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients
    D Minardi
    Institute of Urology, University of Ancona Medical School, Ancona, Italy
    Urol Int 67:272-82. 2001
    The aim of our study was to evaluate the clinical usefulness of percent free prostate-specific antigen (PSA) [ratio of free PSA (fPSA) to total PSA (tPSA); f/tPSA] in prostatic pathology and its usefulness in monitoring prostatic cancer ..
  67. ncbi Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids
    J Lovgren
    Department of Laboratory Medicine, Lund University, University Hospital, Malmo, Sweden
    J Androl 20:348-55. 1999
    It has been demonstrated that prostate-specific antigen (PSA), in spite of its name, can be detected in body fluids and tumors from a variety of organs...
  68. ncbi R75251 in prostate cancer patients in progression after first-line hormonal treatment
    F Boccardo
    Department of Medical Oncology II, National Institute for Cancer Research, Genoa, Italy
    Tumori 80:276-9. 1994
    ..In addition, 2 of them showed a more than 50% decrease of prostate-specific antigens (PSA). Overall, 50% of patients showed some decrease in PSA baseline levels. Overall tolerance to treatment was good...
  69. ncbi Percent of free serum prostate-specific antigen and histological findings in patients undergoing open prostatectomy for benign prostatic hyperplasia
    V Scattoni
    Department of Urology, Scientific Institute H San Raffaele, Milan, Italy
    Eur Urol 36:621-30. 1999
    ..of the surgical specimen in men undergoing open prostatectomy for benign prostatic hyperplasia (BPH) correlate with preoperative and postoperative total, free prostate-specific antigen (PSA) levels and the free-to-total PSA ratio.
  70. pmc Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer
    P S Bunting
    Department of Laboratory Medicine, Sunnybrook and Women s College Health Sciences Centre, Ont
    CMAJ 160:70-5. 1999
    The use of the prostate-specific antigen (PSA) test has been increasing rapidly in Canada since its introduction in 1988. The reasons for using the PSA test in patients without known prostate cancer are unclear...
  71. ncbi Prostate specific antigen density correlates with features of prostate cancer aggressiveness
    Shilajit D Kundu
    Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Urol 177:505-9. 2007
    An increased prostate specific antigen density (serum prostate specific antigen divided by prostate volume) is an established parameter to help determine the need to perform prostate biopsies...
  72. pmc Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy
    Ahmed Magheli
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 179:1780-4; discussion 1784. 2008
    The usefulness of prostate specific antigen density for predicting pathological stage and biochemical recurrence after radical prostatectomy has not been well defined...
  73. pmc Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging
    Stacy Loeb
    The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions and National Institute on Aging, National Institutes of Health Clinical Research Branch, Baltimore, Maryland, USA
    J Urol 180:1314-7; discussion 1317. 2008
    Although prostate specific antigen velocity was proposed to increase the specificity of prostate specific antigen-based screening, there are little published data on the effect of differential prostate growth on prostate specific antigen ..
  74. doi Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience
    Ahmed Magheli
    Department of Urology, Charité Hospital Berlin, Campus Mitte, University Medicine Berlin, Berlin, Germany
    J Urol 183:126-31. 2010
    We investigated the value of pretreatment prostate specific antigen density to predict Gleason score upgrading in light of significant changes in grading routine in the last 2 decades.
  75. ncbi Enhanced expression of prostate-specific antigen in the transition zone of the prostate. A characterization following prostatectomy for benign hyperplasia
    F Recker
    Urological Clinic, Kantonsspital Aarau, Switzerland
    Eur Urol 33:549-55. 1998
    To determine whether the serum levels of total prostate-specific antigen (t-PSA), free PSA (f-PSA) and PSA complexed to alpha 1-antichymotrypsin (PSA-ACT) result from different expressions in various prostatic zones.
  76. ncbi Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA
    Cuneyt Ozden
    Second Urology Clinic of Ankara Numune Education and Research Hospital, Ankara, Turkey
    Urol Int 71:150-3. 2003
    To evaluate early postoperative results of patients with elevated prostate-specific antigen (PSA) levels who underwent surgery due to benign prostatic hyperplasia (BPH).
  77. ncbi Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening
    Judd W Moul
    Division of Urology and Duke Prostate Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Urol 177:499-503; discussion 503-4. 2007
    We identified age adjusted prostate specific antigen and prostate specific antigen velocity cut points for prostate cancer biopsy.
  78. ncbi The association between total prostate specific antigen concentration and prostate specific antigen velocity
    XiaoYing Yu
    Department of Urology, Northwestern Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Urol 177:1298-302; discussion 1301-2. 2007
    It has been previously demonstrated that a prostate specific antigen velocity greater than 2 ng/ml per year is associated with reduced cancer specific survival following radical prostatectomy or external beam radiation...
  79. ncbi Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to 10.0 ng/ml
    J James Bruno
    Department of Surgery, Division of Urology, Lenox Hill Hospital, New York, New York 10021, USA
    J Urol 177:1741-4. 2007
    Percent free prostate specific antigen and prostate specific antigen density have been independently shown to increase the specificity of prostate cancer screening in men with prostate specific antigen levels between 4.1 and 10.0 ng/ml...
  80. ncbi Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml
    Stacy Loeb
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 178:2348-52; discussion 2352-3. 2007
    A prostate specific antigen velocity threshold of 0.75 ng/ml per year has commonly been used to distinguish men with prostate cancer from those with benign prostate conditions...
  81. doi Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer
    Yong Hyun Park
    Department of Urology, Seoul National University Hospital, Seoul, Korea
    J Urol 181:2520-4; discussion 2525. 2009
    We determined the clinical significance of prostate specific antigen half-time and prostate specific antigen doubling time after the prostate specific antigen nadir as predictors of the response to androgen deprivation therapy for ..
  82. pmc [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study
    Brian V Le
    Department of Urology, Northwestern University, Chicago, Illinois 60611, USA
    J Urol 183:1355-9. 2010
    Due to the limited specificity of prostate specific antigen for prostate cancer screening, there is an ongoing search for adjunctive biomarkers...
  83. ncbi Usefulness of prostate-specific antigen velocity in screening for prostate cancer
    Kazuto Ito
    Department of Urology, Gunma University School of Medicine, Maebashi, Japan
    Int J Urol 9:316-21. 2002
    ..of prostate-specific antigen velocity (PSAV) was investigated in relation to the initial prostate-specific antigen (PSA) value in subjects with initial values of 1.0-4...
  84. ncbi Prostate-specific antigen spikes after permanent prostate brachytherapy
    Gregory S Merrick
    Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV 26003 6300, USA
    Int J Radiat Oncol Biol Phys 54:450-6. 2002
    To evaluate whether any clinical, treatment, or dosimetric parameters correlated with the development of a prostate-specific antigen (PSA) spike after permanent prostate brachytherapy.
  85. ncbi Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-sp
    Bob Djavan
    Department of Urology, University of Vienna, Austria
    Urology 60:4-9. 2002
    ..Cancer Detection study evaluated the value and performance of the molecular forms of prostate-specific antigen (PSA) and their derivatives in combination with prostate gland and transition zone volumes in early detection of ..
  86. ncbi Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues
    T Bjork
    Department of Urology, Malmö and Lund University Hospitals, Lund University, Malmo, Sweden
    Prostate 47:14-20. 2001
    Our recently reported finding of rapid bi-exponential elimination of free prostate-specific antigen (PSA) after radical retropubic prostatectomy in patients with moderately elevated PSA levels, which contrasted a very slow, linear ..
  87. ncbi Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter
    Wolfgang Horninger
    Department of Urology, University of Innsbruck, Austria
    Urology 60:31-5. 2002
    Complexed PSA (cPSA) has been shown to improve specificity in the detection of prostate cancer over that of total PSA (tPSA) testing in men with tPSA values greater than the cutoff value of 4.0 ng/mL...
  88. ncbi Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, TX 78229, USA
    JAMA 294:66-70. 2005
    Three fourths of US men older than 50 years have been screened with prostate-specific antigen (PSA) for prostate cancer.
  89. pmc Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database
    Robert J Hamilton
    Division of Urologic Surgery, Department of Surgery, Duke University School of Medicine, Durham, North Carolina 27710, USA
    J Urol 179:1785-9; discussion 1789-90. 2008
    b>Prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy is a powerful predictor of prostate cancer specific and overall death...
  90. ncbi Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer
    H B Carter
    Department of Urology, Johns Hopkins Hospital, Baltimore, MD 21287 2101, USA
    JAMA 277:1456-60. 1997
    To evaluate prostate-specific antigen (PSA) testing intervals that maintain the detection of curable cancer and reduce unnecessary testing.
  91. ncbi Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial
    W J Catalona
    Division of Urologic Surgery, Washington University School of Medicine, St Louis, MO 63110, USA
    JAMA 279:1542-7. 1998
    The percentage of free prostate-specific antigen (PSA) in serum has been shown to enhance the specificity of PSA testing for prostate cancer detection, but earlier studies provided only preliminary cutoffs for clinical use.
  92. doi Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment)
    Simon M Collin
    Department of Social Medicine, University of Bristol, Bristol, UK
    BJU Int 102:1400-6. 2008
    To determine associations of lower urinary tract symptoms (LUTS) with prostate-specific antigen (PSA) levels and screen-detected localized and advanced prostate cancer.
  93. ncbi Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening
    Kazuto Ito
    Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan
    Cancer 103:242-50. 2005
    In the current study, the authors set out to investigate the possibility that increased prostate-specific antigen (PSA) levels in Dutch and Japanese men without suspicious findings at initial prostate cancer screening were indicative of ..
  94. ncbi [Clinical value of prostate specific antigen screening in early detection of prostate cancer]
    Li Xin Hua
    Department of Urological Surgery, First Affiliated Hospital, Nanjing Medical University, Nanjing, China
    Zhonghua Zhong Liu Za Zhi 31:705-9. 2009
    To evaluate the clinical significance of prostate-specific antigen (PSA) screening in early detection of prostate cancer in Chinese men.
  95. ncbi Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia
    C A Mochtar
    Department of Urology, Academic Medical Centre, University of Amsterdam, G4 105 1, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Eur Urol 44:695-700. 2003
    To assess the ability of serum prostate specific antigen (PSA) to estimate prostate volume (PV) to aid in the management of patients with benign prostatic hyperplasia (BPH).
  96. ncbi Serum prostate-specific antigen concentration is increased in acromegalic women
    L Manetti
    Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy
    J Endocrinol Invest 27:643-7. 2004
    Prostate-specific antigen (PSA) is a serine proteases produced by prostatic epithelial cells detectable in male serum and seminal plasma...
  97. ncbi Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate
    P Henttu
    Biocenter, University of Oulu, Finland
    Int J Cancer 45:654-60. 1990
    Human glandular kallikrein-1 gene (hGK-1) is closely related to the gene of human prostate-specific antigen (PSA) and both genes are expressed in the human prostate...
  98. ncbi Clinical usefulness of free PSA in early detection of prostate cancer
    H J Luboldt
    Klinik und Poliklinik fur Urologie, Kinderurologie und Urologische Onkologie, Universitatsklinikum Essen, Gesamthochschule Essen, Essen
    Onkologie 24:33-7. 2001
    Measurement of serum prostate-specific antigen (PSA) is widely used as an aid in early detection of prostate cancer. Most patients with prostate cancer and a PSA level less than 10.0 ng/ml have early-stage disease...
  99. ncbi Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men
    M Sheikh
    Department of Radiology, Faculty of Medicine, Kuwait University, P O Box 24923, 13110, Safat, Kuwait
    Int Urol Nephrol 37:721-6. 2005
    This study was undertaken to assess the utility of prostate specific antigen (PSA) and PSA density (PSAD) in discriminating between benign and malignant prostate disease in the Kuwaiti Arab population.
  100. ncbi Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day)
    Sittiporn Srinualnad
    Division of Urology, Department of Surgery, Faculty of Medicine, Siriraj Hospital 10700, Thailand
    J Med Assoc Thai 89:37-42. 2006
    ..The prevalence of prostate cancer continues to rise. Serum PSA (Prostate Specific Antigen) can be used as a screening tool for detection of early prostate cancer However, a screening program for ..
  101. doi Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer
    Darren M Mitchell
    Department of Clinical Oncology, Christie NHS Trust, Manchester, UK
    Radiother Oncol 88:102-7. 2008
    ..To report on the incidence of benign prostate-specific antigen bounce following permanent I(125) prostate brachytherapy, to describe the associations in our population and review the relationship of bounce to subsequent biochemical failure...

Research Grants80

  1. Pamela L Paris; Fiscal Year: 2015
    ..The advent of widespread PSA (prostate specific antigen) screening has resulted in increased detection of prostate cancer and detection at earlier stages of ..
  2. Kathryn Radabaugh Nightingale; Fiscal Year: 2014
    ..States and Europe to detect PCa, which include digital rectal examination (DRE), and prostate-specific antigen (PSA) analysis...
  3. A Serum Marker for Aggressive Prostate Cancer
    Donna M Peehl; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The PSA era is over. In the U.S...
  4. Alicia C McDonald; Fiscal Year: 2015
    ..DESCRIPTION (provided by applicant): Prostate cancer is one of the most common cancers in U.S. men. Serum prostate specific antigen (PSA) test, a biomarker of prostate cancer, and the digital rectal examination (DRE) have been used for ..
  5. Detecting Prostate Cancer using multi-protocol 3 Tesla in vivo MRI and MRS
    Anant Madabhushi; Fiscal Year: 2009
    ..The current protocol to diagnose CAP in the USA is to have patients with elevated prostate specific antigen (PSA) levels undergo a trans-rectal ultrasound (TRUS)-directed biopsy...
  6. A bioelectronic assay for PSA activity
    Dimitra Georganopoulou; Fiscal Year: 2010
    ..The principal goal of this SBIR proposal is to develop an assay for prostate-specific antigen (PSA) proteolytic enzyme activity to improve the early diagnosis and prognosis of prostate cancer...
  7. Sebastiano Gattoni-Celli; Fiscal Year: 2016
    ..enroll 136 Veteran subjects (68 participants per arm), diagnosed with low-risk prostate cancer (Gleason score d6, PSA d10, clinical stage T1C or T2a)...
  8. Glycan Biomarkers of Prostate Cancer in Prostatic Fluids
    Richard R Drake; Fiscal Year: 2012
    Prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) are glycoproteins secreted by prostate epithelial cells, and have a long clinical history of use as serum biomarkers of prostate cancers...
  9. DAVID MICHAEL SCHUSTER; Fiscal Year: 2016
    ..Approximately 50% of patients who have undergone post-prostatectomy radiotherapy after Prostate Specific Antigen (PSA) failure or biopsy proven prostate bed recurrence manifest subsequent systemic disease, in part, ..
  10. Russell S Taichman; Fiscal Year: 2015
    ..localized prostate cancer (PCa) when he presented for a routine physical exam and was found to have a prostate specific antigen (PSA) blood test of 5.2...
  11. Development of Nonhuman Primate Models for PSA Biology Studies
    JAMES NKAMBWE MUBIRU; Fiscal Year: 2013
    ..These diseases are a cause of significant mortality and morbidity. Prostate specific antigen (PSA) is released at increased levels into the blood early in the development of these diseases and ..
  12. Robot-Assisted MRI-Guided Prostate Biopsy
    Dan Stoianovici; Fiscal Year: 2010
    ..6 billion. Biopsies are typically triggered by elevated prostate specific antigen (PSA) tests, which are highly sensitive but insufficiently specific for PC...
  13. Prostate Cancer Detection by Molecular Urinalysis
    Christian P Pavlovich; Fiscal Year: 2010
    ..S. men >55 years of age over a 7 year period. Currently used screening tests (serum prostate-specific antigen (PSA) and digital rectal exam) have shown only modest predictive value, and serum PSA isoforms have added little ..
  14. A Molecular targeting agent for systemic radiotherapy of metastatic Prostate Canc
    Kevin P Maresca; Fiscal Year: 2010
    ..Blood PSA (Prostate Specific Antigen) screening and digital rectal exams can detect early warning signs of prostate cancer but an effective ..
  15. Small Integrin-binding Glycophosphoproteins as Biomarkers for Prostate Cancer
    Neal S Fedarko; Fiscal Year: 2013
    ....
  16. Glycoproteins and Glycan-Binding IgGs: Biomarkers for Cancer and Inflammatory Di
    Hyesook Kim; Fiscal Year: 2013
    ..Increased prostate-specific antigen (PSA) coreprotein levels have been widely used to detect, stage and monitor prostate cancer...
  17. Tatiana Khokhlova; Fiscal Year: 2016
    ..g., Prostate Specific Antigen (PSA) tests, often fail to differentiate between the two...
  18. Tea Polyphenols in Chemoprevention of Prostate Cancer
    SUSANNE MARGARETE HENNING; Fiscal Year: 2011
    ..Serum prostate specific antigen and IGF-1/IGFBP-3 will be determined using chemiluminescent analysis...
  19. Robert J Klein; Fiscal Year: 2016
    ..year, over 1,000,000 needless prostate biopsies are performed on men who present with elevated levels of prostate specific antigen (PSA) but show no evidence of cancer upon biopsy...
  20. Proximal Prostate Fluids for Protein and miRNA Biomarkers
    Richard R Drake; Fiscal Year: 2010
    Detection of prostate specific antigen (PSA) levels in serum as a biomarker of prostate cancer continues to evolve to reflect new knowledge about disease-specific isoforms and free versus bound complexes with serum proteins...
  21. [F18]FMAU in Prostate Cancer
    Hossein Jadvar; Fiscal Year: 2010
    ..Approximately 30% of men with detectable serum prostate-specific antigen (PSA) levels after curative radical prostatectomy have local recurrences while about 40% are expected to have distant ..
  22. Single Molecule Fiber Arrays for the Detection of Low Abundance Proteins
    David C Duffy; Fiscal Year: 2013
    ..Using single molecule detection, prostate specific antigen (PSA) was detected in serum at concentrations less than 1 femtomolar;current immunoanalyzers have an LOD ..
  23. Gene Networks for Prostate Cancer Progression
    Leif Peterson; Fiscal Year: 2005
    ..tissue during radical retropubic prostatectomy (RPP) and short doubling time (<10 months) for serum prostate specific antigen (PSA)...
  24. Genetic Susceptibility for Prostate Cancer Progression
    William Isaacs; Fiscal Year: 2009
    ..As many as 25% or more men who undergo this treatment will experience a re-elevation in their serum Prostate Specific Antigen (PSA) level within months to years later...
  25. James Marshall; Fiscal Year: 2015
    ..Diet change will be evaluated by 24-hour recalls and by blood carotenoids. Disease will be monitored by PSA and appropriate clinical surveillance for 24 months...
  26. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    Mona Fouad; Fiscal Year: 2013
    ..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
  27. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    BARBARA O'BRIEN; Fiscal Year: 2013
    ..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
  28. Detection of Prostate Cancer Genomic Signatures in Blood
    Amin I Kassis; Fiscal Year: 2010
    ..The diagnosis of prostate cancer (PC) is usually subsequent to routine prostate-specific antigen (PSA) determination in blood and/or discovery of a palpable mass within the prostate (following rectal examination) that ..
  29. PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL
    Paul Kvale; Fiscal Year: 2010
    ..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
  30. PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL
    KAREN STEINMETZ; Fiscal Year: 2011
    ..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
  31. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    Mona Fouad; Fiscal Year: 2011
    ..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
  32. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    BARBARA O'BRIEN; Fiscal Year: 2011
    ..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
  33. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    Saundra Buys; Fiscal Year: 2009
    ..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
  34. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    Mona Fouad; Fiscal Year: 2009
    ..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
  35. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    Mona Fouad; Fiscal Year: 2010
    ..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
  36. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    BARBARA O apos BRIEN; Fiscal Year: 2009
    ..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
  37. PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL
    Claudine Isaacs; Fiscal Year: 2009
    ..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
  38. Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial - Lab
    Cheryl Robinson; Fiscal Year: 2009
    ..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
  39. PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL
    Claudine Isaacs; Fiscal Year: 2010
    ..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
  40. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    BARBARA O apos BRIEN; Fiscal Year: 2010
    ..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
  41. WILLIAM GEORGE NELSON; Fiscal Year: 2016
    ..The Research Projects are supported by an Administrative Core (A), which also manages inter-SPORE collaborations, a Tissue Archive Core (B), and a Biostatistics and Epidemiology Core (C). ..
  42. Martin G Pomper; Fiscal Year: 2016
    ..The ability to fulfill that goal would eliminate the prostate-specific antigen (PSA)-mediated overdetection and overtreatment of clinically insignificant disease...
  43. The Role of MicroRNAs in Prostate Cancer Progression
    AURORA ESQUELA KERSCHER; Fiscal Year: 2010
    ..Prostate-specific antigen (PSA) is a widely used diagnostic marker for prostate cancer that can result in the treatment of insignificant disease ..
  44. Hari K Koul; Fiscal Year: 2014
    ..Tet inhibited Prostate Specific Antigen (PSA) synthesis and secretion, blocked cell cycle progression and growth of human PCa cells in culture, ..
  45. Decision Making in Unaffected First-Degree Relatives of Prostate Cancer Patients
    Clement Gwede; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): The use of the prostate specific antigen (PSA) test in the general population and identifiable high-risk subgroups remains controversial, and the PSA test remains the only available test to date to ..
  46. Identification of Colon Cancer Protein Biomarkers in the Blood
    WILFRIDO DIOKNO MOJICA; Fiscal Year: 2010
    ..approaches suggest the potential to identify candidate CRC-selective biomarker proteins, akin to Prostate Specific Antigen (PSA) for prostate cancer or CA125 for ovarian cancer...
  47. Methylated Galectin-3 DNA as a Marker for Early Diagnosis of Prostate Cancer
    Hafiz Ahmed; Fiscal Year: 2010
    ..Combined with the digital rectal examination, the prostate specific antigen (PSA) test has been widely used to detect prostate cancer in its early stages...
  48. MATHEW LAXMAN THAKUR; Fiscal Year: 2016
    ..Serum prostate specific antigen (PSA) measurements, transrectal ultrasonography (TRUS) and magnetic resonance imaging (MRI) remain ..
  49. Alpha Methyl AcylCoa Racemase (AMACR)
    Martin G Pomper; Fiscal Year: 2010
    ..The ability to fulfill that goal would eliminate the prostate-specific antigen (PSA)-mediated over detection and overtreatment of clinically insignificant disease...
  50. Decision Making For Active Surveillance in Prostate Cancer Patients and Spouses
    Christian J Nelson; Fiscal Year: 2013
    ..Over the past years, widespread prostate specific antigen (PSA) screening has resulted in the earlier detection of these cancers...
  51. Complementary and Alternative Medicine for Urological Symptoms (CAMUS)
    Andrew L Avins; Fiscal Year: 2010
    ....
  52. Tianying Wu; Fiscal Year: 2014
    ..Public Health Implications: (1) Prostate-specific antigen (PSA) screening has low specificity but high sensitivity. Our goal is to complement PSA screening...
  53. Metabolomic Markers for Early Detection of Prostate Cancer
    Arun Sreekumar; Fiscal Year: 2010
    ..Clinically, early detection of prostate cancer is guided by levels of prostate specific antigen (PSA)...
  54. Effects of Stereotype Threat on the Health-Related Outcomes of African Americans
    Paul R Jones; Fiscal Year: 2011
    ..If threat is a problem, the project will develop guidelines for designing health communication and refining cultural competency training and practice that avoid raising stereotype threat. ..
  55. Prostate-Specific Antigen Practices and Outcomes in the Elderly
    Louise C Walter; Fiscal Year: 2013
    Project Summary/Abstract Prostate-specific antigen (PSA) screening for the early detection of prostate cancer has been widely adopted in the U.S. among elderly men, including those with limited life expectancy...
  56. Leo L Cheng; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Serum prostate specific antigen testing improved early detection of prostate tumors, increased diagnosed prostate cancer (PCa) incidence, and shifted newly detected PCa treatment to earlier stages...
  57. Andrew J Vickers; Fiscal Year: 2015
    ..are unnecessary: the most common reason for a prostate biopsy is an elevated level of prostate-specific antigen (PSA) in the blood, but most men with elevated PSA do not have prostate cancer...
  58. Emanuela Taioli; Fiscal Year: 2014
    ..g., over-diagnosis because of enhanced surveillance and screening with prostate specific antigen [PSA]) would represent an important message to WTCHP members...
  59. ROBIN JEAN LEACH; Fiscal Year: 2014
    ..for control of this disease is currently early diagnosis and treatment, relying primarily on the Prostate Specific Antigen (PSA) blood test for detection. Unfortunately, for most men with a PSA above 4...
  60. Jennifer Dacey Allen; Fiscal Year: 2014
    ..5 times more likely to die from the disease than White men. Screening with prostate specific antigen (PSA) is the main method of early detection, although it remains of unproven benefit...
  61. Daniel B Vigneron; Fiscal Year: 2016
    ..Due to increased screening using serum prostate specific antigen (PSA) and extended-template transrectal ultrasound (TRUS) guided biopsies, patients with prostate cancer ..
  62. Sarah E Woolf-King; Fiscal Year: 2016
    ..We will accomplish this aim by: (a) using a qualitative test for Prostate Specific Antigen (PSA), an indicator of recent (i.e...
  63. Stephen K Van Den Eeden; Fiscal Year: 2015
    DESCRIPTION (provided by applicant): The advent of prostate-specific antigen (PSA) testing in the late 1980s has led to a dramatic rise in prostate cancer (PCa) incidence...
  64. Grace Lu-Yao; Fiscal Year: 2014
    ..follow-up and unavailability of key prognostics factors such as detailed Gleason scores and baseline prostate specific antigen (PSA) data...
  65. Real-time detection of cancer biomarkers using a self-sustained aptazyme
    Charles Olea; Fiscal Year: 2013
    ..As proof-of-principle, two aptazymes specific for cancer biomarkers prostate-specific antigen (PSA) and p21-activated kinase (PAK1) will be developed...
  66. Profiling Urine Glycosylation of PSA and other Glyco-Biomarkers in Prostate Cance
    Lewis Pannell; Fiscal Year: 2009
    ..We observed significant levels of both prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) in the urine from healthy individuals, consistent with some ..
  67. ACTIVATION OF PROSTATE SPECIFIC ANTIGEN PRECURSOR
    Thomas Takayama; Fiscal Year: 2000
    b>Prostate specific antigen (PSA) is a prostatic enzyme with biological significance. As a proteolytic enzyme, it cleaves seminal coagulum proteins to release sperm for fertilization...
  68. Early detection of prostate cancer in urine
    Hafiz Ahmed; Fiscal Year: 2010
    ..Combined with the digital rectal examination, the prostate specific antigen (PSA) test has been widely used to detect prostate cancer in its early stages...
  69. FORMS OF PROSTATE SPECIFIC ANTIGEN AND HK2 IN CANCER
    MARY HEEB; Fiscal Year: 2003
    We seek to extend promising studies showing that prostate specific antigen (PSA) and glandular kallikrein (hK2) occur in several forms in blood of prostate cancer (CaP) patients and that measurement of the proportion of PSA in the form ..
  70. The functions of affect in treatment decicions of rising PSA patients
    Michael A Diefenbach; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The widespread use of prostate-specific antigen (PSA) testing has enabled physicians to closely monitor patients who have been treated for prostate cancer...
  71. Anti-GM1b IgM for Detection of Localized Prostate Cancer
    Mepur Ravindranath; Fiscal Year: 2005
    ..Prostate-specific antigen (PSA) is widely used for diagnosing and monitoring CaP...
  72. Development of an anti-PSA IgE to treat prostate cancer
    Birgit Schultes; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): The present proposal seeks to develop a novel anti-prostate specific antigen (PSA) IgE antibody for the treatment of prostate cancer (PCA) with the goal to induce a hypersensitivity reaction to the ..

Patents1

  1. Human cDNAs and proteins and uses thereof
    Patent Number: WO03046180-A2; Date:2003-06-05